ARDX Quote, Financials, Valuation and Earnings

BridgeBio Pharma has a net margin of 4% compared to Ardelyx's net margin of -143.55%. Ardelyx's return on equity of -24.57% beat BridgeBio Pharma's return on equity of --.

Ardelyx has a consensus price target of $9.85, signalling upside risk potential of 138.5%. On the other hand BridgeBio Pharma has an analysts' consensus of $57.72 which suggests that it could grow by 49.66%. Given that Ardelyx has higher upside potential than BridgeBio Pharma, analysts believe Ardelyx is more attractive than BridgeBio Pharma.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $116.1M, which are smaller than BridgeBio Pharma quarterly revenues of $116.6M. Ardelyx's net income of $4.6M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Ardelyx's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.91x versus 57.19x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of 4% compared to Ardelyx's net margin of -225.53%. Ardelyx's return on equity of -24.57% beat Insmed's return on equity of -41989.34%.

Ardelyx has a consensus price target of $9.85, signalling upside risk potential of 138.5%. On the other hand Insmed has an analysts' consensus of $97.12 which suggests that it could grow by 34.34%. Given that Ardelyx has higher upside potential than Insmed, analysts believe Ardelyx is more attractive than Insmed.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison Insmed has a beta of 0.837, suggesting its less volatile than the S&P 500 by 16.28%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $116.1M, which are larger than Insmed quarterly revenues of $104.4M. Ardelyx's net income of $4.6M is higher than Insmed's net income of -$235.5M. Notably, Ardelyx's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.91x versus 32.60x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of 4% compared to Ardelyx's net margin of 3.45%. Ardelyx's return on equity of -24.57% beat Repligen's return on equity of -1.16%.

Ardelyx has a consensus price target of $9.85, signalling upside risk potential of 138.5%. On the other hand Repligen has an analysts' consensus of $183.13 which suggests that it could grow by 29.41%. Given that Ardelyx has higher upside potential than Repligen, analysts believe Ardelyx is more attractive than Repligen.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison Repligen has a beta of 1.207, suggesting its more volatile than the S&P 500 by 20.699%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $116.1M, which are smaller than Repligen quarterly revenues of $169.2M. Ardelyx's net income of $4.6M is lower than Repligen's net income of $5.8M. Notably, Ardelyx's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.91x versus 12.24x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of 4% compared to Ardelyx's net margin of 40.56%. Ardelyx's return on equity of -24.57% beat United Therapeutics's return on equity of 19.92%.

Ardelyx has a consensus price target of $9.85, signalling upside risk potential of 138.5%. On the other hand United Therapeutics has an analysts' consensus of $388.18 which suggests that it could grow by 31.77%. Given that Ardelyx has higher upside potential than United Therapeutics, analysts believe Ardelyx is more attractive than United Therapeutics.

Ardelyx has a beta of 0.762, which suggesting that the stock is 23.846% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.76%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $116.1M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Ardelyx's net income of $4.6M is lower than United Therapeutics's net income of $322.2M. Notably, Ardelyx's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 11.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.91x versus 4.75x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.